Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Pharmicell Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05093881CT.gov Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study | — | Recruiting | — | — | — |
NCT04689152CT.gov Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcoholic Liver Cirrhosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cellgram-Lc (this asset) | Pharmicell Co., Ltd. | P3 | B · 60 |
| Losartan | Odense University Hospital | P4 | BB |
| Allogeneic Mesenchymal Stem Cells | Stempeutics Research Pvt Ltd | P2 | B |
| Livercellgram | Pharmicell Co., Ltd. | P2 | B |
| Nivestim | Yaqrit Ltd | P2 | CCC |
| Resatorvid | Yaqrit Ltd | P2 | CCC |
| S,S-Adenosylmethionine | Indiana University | P2 | CCC |
| Rosuvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | CCC |
| Baclofen | Corporacion Parc Tauli | P1/2 | CCC |
+3 more in the Alcoholic Liver Cirrhosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cellgram-Lc in Alcoholic Liver Cirrhosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cellgram-lc-alcoholic-liver-cirrhosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →